Investigational drug · Phase 3
ONC-392
Also called: Gotistobart, BNT316
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
6
Any phase or sponsor naming "ONC-392"
First trial start
2020
Sep 16, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ONC-392", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Small Cell Lung Cancer
- Ovarian Cancer
- Advanced Solid Tumor
- Metastatic Castration-resistant Prostate Cancer
- High Grade Serous Adenocarcinoma of Ovary
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Metastatic Melanoma
- Metastatic Head and Neck Carcinoma
- Metastatic Renal Cell Carcinoma
Approved drugs for the same conditions: Small cell lung cancer · Prostate cancer · Melanoma · Ovarian cancer · Kidney cancer (renal cell carcinoma) · Head and neck cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ONC-392" as an intervention, largest first.
- Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruiting
OncoC4, Inc.Industry
NCT04140526 · 733 participants (planned) · Start Sep 16, 2020 · Primary completion Dec 31, 2026
Drug: ONC-392; Pembrolizumab and 1 more · For: Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma and 16 more
Sites: Springdale, Arkansas; Davis, California; Downey, California · 37 sites in all
- ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsPivotal-lookingActive, not recruiting
OncoC4, Inc.Industry
NCT05671510 · 630 participants (planned) · Start Jun 28, 2023 · Primary completion Aug 31, 2027
Drug: Gotistobart; Docetaxel · For: Non Small Cell Lung Cancer
Sites: Dothan, Alabama; Russellville, Arkansas; Cerritos, California · 152 sites in all
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPCPivotal-lookingActive, not recruiting
OncoC4, Inc.Industry
NCT05682443 · 148 participants · Start Dec 11, 2023 · Primary completion Nov 30, 2026
Drug: ONC-392 low; ONC-392 high and 1 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Sacramento, California; Aurora, Colorado; Tampa, Florida · 23 sites in all
- ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerActive, not recruiting
OncoC4, Inc.Industry
NCT05446298 · 58 participants · Start Dec 22, 2022 · Primary completion Aug 30, 2026
Drug: ONC-392; Pembrolizumab · For: Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma and 1 more
Sites: Goodyear, Arizona; Phoenix, Arizona; Danbury, Connecticut · 21 sites in all
- Gotistobart Long Term Extension (LTE) StudyPivotal-lookingEnrolling by invitation
OncoC4, Inc.Industry
NCT07659379 · 20 participants (planned) · Start Jul 28, 2026 · Primary completion Jul 1, 2036
Drug: Gotistobart · For: Advanced Solid Tumor
Sites: Fort Worth, Texas; Tyler, Texas
OncoC4, Inc.Industry
NCT05858736 · 18 participants · Start Jul 11, 2023 · Primary completion Jul 31, 2026
Drug: AI-061 · For: Melanoma; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma and 14 more
Sites: Darlinghurst, Australia; Brisbane, Australia; Southport, Australia · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Population pharmacokinetics for the CTLA-4 modulator gotistobart in patients with advanced solid tumors.
Li T, Xue J, Liu Y, et al. · J Clin Pharmacol 2026
- Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
Cho BC, Balaraman R, Chen HJ, et al. · Nat Med 2026
- Pembrolizumab in mCRPC - Combination therapies as breakthrough to success?
Plas S, Pircher A, Heidegger I · Curr Opin Urol 2023
Also in development for Non Small Cell Lung Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- DomvanalimabAB154, GS-0154Phase 310 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- SI-B001Phase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.